New hope for lymphoma patients: experimental drug combo enters final testing phase
NCT ID NCT07562022
First seen May 04, 2026 · Last updated May 19, 2026 · Updated 3 times
Summary
This study tests whether a new drug called SCTB35, when combined with lenalidomide, works better than the standard combination of rituximab and lenalidomide for people with follicular lymphoma that has returned or stopped responding to prior therapy. About 93 adults aged 18-80 will take part. The goal is to see if the new combination can delay cancer growth and has acceptable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.